Aug 1, 2007 1 Conducting Cost-Effectiveness Analyses of Behavioral Interventions Todd H. Wagner, Ph.D. Mary K. Goldstein, M.D. Mary K. Goldstein, M.D.

Slides:



Advertisements
Similar presentations
Exploring uncertainty in cost effectiveness analysis NICE International and HITAP copyright © 2013 Francis Ruiz NICE International (acknowledgements to:
Advertisements

Understanding Those Who Do and Do Not Plan to Get Colorectal Cancer (CRC) Screening Costanza ME, White MJ, Stark JR, Stoddard AM, Avrunin JS, Luckmann.
Advancing Health Economics, Services, Policy and Ethics An Application of Evidence-Based Marginal Analysis: Assessing the Incremental Cost Effectiveness.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Introduction to decision modelling Andrew Sutton.
Economic Analysis and Management Todd Wagner, PhD.
Recommendations for Conducting Cost Effectiveness: Elements of the Reference Case Ciaran S. Phibbs, Ph.D. February 25, 2009.
The Importance of Decision Analytic Modelling in Evaluating Health Care Interventions Mark Sculpher Professor of Health Economics Centre for Health Economics.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan UNC: November, 2003.
Journal Club Alcohol and Health: Current Evidence March-April 2006.
Clinical trials methodology group Simon Gates 9 February 2006.
Analysis Alongside A Randomized Trial Todd Wagner, PhD May 2009.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan ACSIR, July, 2003.
An Experimental Paradigm for Developing Adaptive Treatment Strategies S.A. Murphy Univ. of Michigan February, 2004.
Health care decision making Dr. Giampiero Favato presented at the University Program in Health Economics Ragusa, June 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2009.
The Panel on Cost-Effectiveness in Health and Medicine Marthe Gold City University of London 30 October, 2003.
Decision Analysis as a Basis for Estimating Cost- Effectiveness: The Experience of the National Institute for Health and Clinical Excellence in the UK.
Sample Size Determination
POST- RANDOMIZATION DATA ANALYSIS OGNEN JAKASANOVSKI
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Assessing cost-effectiveness – what is an ICER?- Incremental analysis
Economic Evaluations, Briefly… CHSC 433 Module 6/Chapter 13 UIC School of Public Health L. Michele Issel, PhD, R N.
Cost Effectiveness Analysis To Enhance Mammography Use Dave Alvey Paul Moley.
Are the results valid? Was the validity of the included studies appraised?
Cost-Effectiveness Problem l You have a $1.5 billion budget to spend on any combination of these programs:
1 Cost Effectiveness of Outreach Interventions for Low-Income Multiethnic Women Todd Wagner, VA & Stanford Rena Pasick, UCSF Stephen McPhee, UCSF Jeanne.
Economics of Implementation: Moving beyond Traditional CEA Mark Smith Paul Barnett VA Health Economics Resource Center.
© 2005, Johns Hopkins University. All rights reserved. Department of Health, Behavior & Society David Holtgrave, PhD, Professor & Chair.
PHAR 310: Pharmacoeconomics
1 Introduction to Grant Writing Beth Virnig, PhD Haitao Chu, MD, PhD University of Minnesota, School of Public Health December 11, 2013.
Sample size determination Nick Barrowman, PhD Senior Statistician Clinical Research Unit, CHEO Research Institute March 29, 2010.
Effects of Pediatric Asthma Education on Hospitalizations and Emergency Department Visits: A Meta-Analysis June 3, 2007 Janet M. Coffman, PhD, Michael.
BACKGROUND Cost-effectiveness of Psychotherapy for Cluster C Personality Disorders and the Value of Information and Implementation Djøra I. Soeteman 1,2,
EHR Goal Setting and Impact on Quality of Care
EBC course 10 April 2003 Critical Appraisal of the Clinical Literature: The Big Picture Cynthia R. Long, PhD Associate Professor Palmer Center for Chiropractic.
Economics of Implementation: Moving beyond Traditional CEA Mark Smith Paul Barnett VA Health Economics Resource Center.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Plymouth Health Community NICE Guidance Implementation Group Workshop Two: Debriding agents and specialist wound care clinics. Pressure ulcer risk assessment.
Cost-Effectiveness and Cost-Benefit Analysis N287E Spring 2006 Joanne Spetz 31 May 2006.
Validation / citations. Validation u Expert review of model structure u Expert review of basic code implementation u Reproduce original inputs u Correctly.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 19: Economic Evaluation using Patient-Level.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
John Q. Wong, MD, MSc 30 September Quiz Ethics of health economics Quick guide to types of economic evaluation Critical appraisal of a CEA article.
How Can Cost Effectiveness Analysis Be Made More Relevant to U.S. Health Care? Paul G. Barnett, PhD February 29, 2012.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Cost-effectiveness of Screening Tests Mark Hlatky, MD Stanford University.
2nd Concertation Meeting Brussels, September 8, 2011 Reinhard Prior, Scientific Coordinator, HIM Evidence in telemedicine: a literature review.
Development and the Role of Meta- analysis on the Topic of Inflammation Donald S. Likosky, Ph.D.
Promoting high quality, cost effective drug therapy throughout the Military Health System Identification and Use of Published Health Economic Evaluations.
Using the Stages of Change Model to Select an Optimal Health Marketing Target Paula Diehr, Ph.D. Health Marketing Research Center CDC Center of Excellence.
SMART Trials for Developing Adaptive Treatment Strategies S.A. Murphy Workshop on Adaptive Treatment Designs NCDEU, 2006.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Jane Cowl, Senior Public Involvement Adviser Tommy Wilkinson,
COPE: Community Parent Education Program Evidence Base and Future Directions Charles E. Cunningham, Ph.D. Professor Department of Psychiatry & Behavioural.
CT Screening for Lung Cancer vs. Smoking Cessation: A Cost-Effectiveness Analysis Pamela M. McMahon, PhD; Chung Yin Kong, PhD; Bruce E. Johnson; Milton.
Adnan K. Chhatriwalla, MD Saint-Luke’s Mid America Heart Institute
Global burden of diseases
How to Perform a Cost-Effectiveness Analysis
A Meta Analysis of the Impact of SBI on Healthcare Utilization
Background & Objectives
Developing a Health Maintenance Schedule
Health care decision making
Outcome-adaptive randomization: some ethical issues
Evaluation of Immunization Standing Orders Programs in North Carolina Hospitals Presented by Wayne L. Anderson Ph.D.1, Amanda Honeycutt Ph.D.1, Kathleen.
A Meta Analysis of the Impact of SBI on Healthcare Utilization
Stamatia Destounis, MD, FACR, FSBI, FAIUM
Use of Piecewise Weighted Log-Rank Test for Trials with Delayed Effect
Creating a good research question…
Diabetic Retinopathy Clinical Research Network
Presentation transcript:

Aug 1, Conducting Cost-Effectiveness Analyses of Behavioral Interventions Todd H. Wagner, Ph.D. Mary K. Goldstein, M.D. Mary K. Goldstein, M.D.

Aug 1, Acknowledgements Partial funding was through a grant from the National Cancer Institute (2PO1 CA A1). Partial funding was through a grant from the National Cancer Institute (2PO1 CA A1). Dr. Goldstein ’ s contribution was informed in part by work conducted with a grant from the National Institute on Aging (R01 AG15110). Dr. Goldstein ’ s contribution was informed in part by work conducted with a grant from the National Institute on Aging (R01 AG15110). David Meltzer, Jodi Prochaska, Lisa Faulkner, and Stanford University seminar participants provided helpful comments. David Meltzer, Jodi Prochaska, Lisa Faulkner, and Stanford University seminar participants provided helpful comments.

Aug 1, Outline of the Talk Background on cost-effectiveness analysis (CEA) Background on cost-effectiveness analysis (CEA) A bias in CEAs for behavioral interventions A bias in CEAs for behavioral interventions How to fix the problem How to fix the problem Example Example Study design consideration Study design consideration

Aug 1, Economic Evaluations Most trials don’t include economic analysis Most trials don’t include economic analysis Economic analysis in only 0.2% of 50,000 trials conducted between Economic analysis in only 0.2% of 50,000 trials conducted between –Adams et al. Medical Care 30(3): Economic analysis in randomized clinical trials is increasing Economic analysis in randomized clinical trials is increasing

Aug 1, Dollars and Sense Economic studies inform decisions Economic studies inform decisions –formulary –adoption of new technology –scope of benefits –strategies for management of care –organization of health care

Aug 1, Cost Effectiveness Ratio Where C 1 is the average cost of the intervention group C 0 is the average cost of the control group E 1 is the average effectiveness of the intervention group E 0 is the average effectiveness of the control group

Aug 1, Standardization USPTF guidelines (Gold et al., 1996; summarized in three JAMA articles) USPTF guidelines (Gold et al., 1996; summarized in three JAMA articles) Drummond et al. (1997) Drummond et al. (1997) Created, along with journal editors, standards for both Created, along with journal editors, standards for both –Methods –Reporting

Aug 1, Whose Costs? Guidelines recommend a societal perspective for costs Guidelines recommend a societal perspective for costs Include Include –Provider –Payer –Patient

Aug 1, Effectiveness Guidelines recommend QALYs Guidelines recommend QALYs Values both quality and quantity of life Values both quality and quantity of life Each year of life is multiplied by a weighting factor (utility) Each year of life is multiplied by a weighting factor (utility) Utilities measure the preference of different health states on a 0-1 scale Utilities measure the preference of different health states on a 0-1 scale

Aug 1, Behavioral Interventions CEA framework holds, but caveats … CEA framework holds, but caveats … –Behavior change is a “ slow ” process –Treat many to prevent a few –Use of intermediate outcomes (proxies)

Aug 1, Intermediate Outcomes Outcome is clinically relevant and predicts mortality or morbidity Outcome is clinically relevant and predicts mortality or morbidity –Receipt of a mammogram –Substance use abstinence –Change in dietary fiber QALYs would require huge and/or very long studies QALYs would require huge and/or very long studies

Aug 1, CEA with an Intermediate Outcome Sufficient for publication Sufficient for publication Hard to interpret ICER Hard to interpret ICER –Can’t easily compare two CEAs with different intermediate outcomes –Can’t compare CEA to other CEA from another clinical area Sometimes only feasible approach Sometimes only feasible approach

Aug 1, CEA with QALYs Measure QALYs or Measure QALYs or Translate intermediate outcome to QALYs Translate intermediate outcome to QALYs –Either build a model de novo or use an existing model –Requires a lot of resources Most useful, but most challenging Most useful, but most challenging

Aug 1, CEA and Behavior Change CEA analysts treat behavior change as a dichotomous outcome CEA analysts treat behavior change as a dichotomous outcome Partial behavior change is not the same as no behavior change Partial behavior change is not the same as no behavior change “ Getting the person to recognize that they have a problem is half the battle. ” “ Getting the person to recognize that they have a problem is half the battle. ”

Aug 1, What ’ s Missing? Partial behavior change is missing from current models Partial behavior change is missing from current models –People who progressed in their process of changing their behavior but did not successfully change their behavior at the end of the study (Stages of Change)

Aug 1, Partial Behavior Change All behavioral interventions yield some partial behavior change All behavioral interventions yield some partial behavior change Amount depends on Amount depends on –the duration of the study –baseline stage of change

Aug 1, Partial Behavior Change Should we and can we value partial behavior change in a CEA?

Aug 1, Should We? NO Intentions are not the same as observed behavior change Intentions are not the same as observed behavior change Stage of change is flawed Stage of change is flawed Too difficult Too difficultYES Behavior change takes time Behavior change takes time Unobservable differences exist Unobservable differences exist Future benefits are important Future benefits are important Otherwise favors med/surg tx Otherwise favors med/surg tx

Aug 1, Can We? Behaviors are like “ value chains ” Behaviors are like “ value chains ” –A series of linked processes –Interventions may be designed to improve a link (stage-matched design)  Matching chemotherapy protocol to cancer stage –Interventions may have differential effects on different links Stages of Change (TTM) Model by Prochaska and DiClimente Stages of Change (TTM) Model by Prochaska and DiClimente

Aug 1, Stages of Change People progress through successive stages until they change their behavior People progress through successive stages until they change their behavior –Precontemplation: no self-recognition of a problematic behavior. –Contemplation: self-recognition of a problem without action. –Preparation: Planning to change behavior soon. –Action: In the process of change. –Maintenance: adherence to the new behavior over time. Art of behavioral interventions is to achieve action, and hopefully maintenance Art of behavioral interventions is to achieve action, and hopefully maintenance

Aug 1, Stages of Change and CEA Stages of change is critical for interpreting CEA results Stages of change is critical for interpreting CEA results –Stage of change may be associated with receptivity or motivation –Intervention effects can vary by stage of change –Incremental cost-effectiveness ratio can vary by stage of change

Aug 1, Integrating Stages of Change in a CEA

Aug 1, What’s Needed? Data on stages of change Data on stages of change Probability of moving from partial to successful behavior change Probability of moving from partial to successful behavior change –Note: these probabilities are not observed in the intervention group

Aug 1, Two Step Process Step 1 Step 1 –Calculate ICERs by baseline stage of change –This alone can provide much more useful and interpretable information for stage-matched interventions Step 2 Step 2 –Estimate probability of people moving into successive stages of change –For example, % moved from precontemplation to contemplation and preparation

Aug 1, Source of the Probabilities Probabilities from the literature or Probabilities from the literature or The control group (if possible) The control group (if possible) –Possible when control group gets usual care –If 10% of precontemplators in the control group changed behavior, this is the probability for the model

Aug 1, Hypothetical Example

Aug 1, Randomized Controlled Trial 2700 participants enrolled in 3 arms 2700 participants enrolled in 3 arms –Post card reminder (n=900) –Reminder phone call (n=900) –Personal motivational phone call (n=900) Sample from managed care plan Sample from managed care plan Managed care organization wants to know which reminder to use Managed care organization wants to know which reminder to use

Aug 1, Cost and Effectiveness

Aug 1, Report to MCO MCO should choose between postcard or reminder call MCO should choose between postcard or reminder call

Aug 1, Transition Probabilities

Aug 1, Including Partial Behavior Change Note motivational call is now most effective overall Note motivational call is now most effective overall

Aug 1, ICERs No single strategy is always preferred. No single strategy is always preferred. Motivational call is dominated by reminder call for contemplators and those in action Motivational call is dominated by reminder call for contemplators and those in action

Aug 1, Origin of These Ideas

Aug 1, Patient Reminders Mailed reminder vs no reminder for mammography Mailed reminder vs no reminder for mammography A meta analysis of 16 studies A meta analysis of 16 studies –US studies Pooled OR=1.48 (participants come from provider files) –Aust / NZ studies Pooled OR=5.57 (participants from voter lists) Wagner TH. The effectiveness of mailed patient reminders on mammography screening: a meta-analysis. Am J Prev Med. 1998;14(1):64-70.

Aug 1, CEA and Stage of Change Fishman P. et al. Cost-effectiveness of strategies to enhance mammography use. Eff Clin Pract Fishman P. et al. Cost-effectiveness of strategies to enhance mammography use. Eff Clin Pract Compared three alternative methods for increasing mammography screening Compared three alternative methods for increasing mammography screening –Reminder postcard –Reminder call –Motivational call

Aug 1, Fishman’s (2000) results ICER varied by prior mammography status (i.e., maintenance) ICER varied by prior mammography status (i.e., maintenance)

Aug 1, Feeling Lucky? The implications of a CEA should not vary by who enters the trial The implications of a CEA should not vary by who enters the trial Two randomized trials with same intervention Two randomized trials with same intervention –RCT 1: all participants are in preparation –RCT 2: all participants are in precontemplation

Aug 1, Clinical Trial Design If the effect of the intervention might vary by stage of change If the effect of the intervention might vary by stage of change –Qx: Enroll people from all stages? –Enroll sufficient numbers in each stage –Protect randomization

Aug 1, Conclusions Subgroup analysis by stage of change may be critical for interpreting the CEA Subgroup analysis by stage of change may be critical for interpreting the CEA Partial behavior change is important and can affect interpretation Partial behavior change is important and can affect interpretation These methods are appropriate for stage- matched studies These methods are appropriate for stage- matched studies Need to consider study design implications Need to consider study design implications